Stock Market Today, Feb: ImmunityBio Up on Anktiva EU OK
ImmunityBio sails higher after the EU green lights ANKTIVA for bladder cancer, igniting waves across biotech stocks. ...
This guide clarifies which investors benefit most from target date funds versus index funds, focusing on goals and involvement level.
26,623 articlesImmunityBio sails higher after the EU green lights ANKTIVA for bladder cancer, igniting waves across biotech stocks. ...
When a big shareholder starts selling, the market pays attention. This article explains what this major investor dump...
When a niche space-data stock jumps, investors want to know the real reasons behind the move. This guide explains why...
Retirees and future retirees are hearing unsettling news about Social Security. This guide shows how to interpret the...
As dxlg posts its 2025 numbers, investors should focus on sales trends, margins, and cash flow. This guide breaks dow...
Wheaton's Q1 2026 earnings transcript offers clues about margins, cash flow, and future growth in the gold streaming ...
A growing number of households report gaps in paid time off and career momentum that ripple into investing and retire...
Rivian has captured imaginations—and capital. But the next 12 months will test its ability to scale, control costs, a...
Builders are flocking to fast-growing regions. This guide explains which markets are rising, why lenders support them...
Drones and government funding chatter are reshaping investor sentiment. Ondas is at the center of the action, with ot...
Tesla faces a pivotal 2H 2026. This guide breaks down the catalysts, the risks, and practical steps investors can tak...
As 2026 unfolds, investors face a pivotal choice between Lyft and Uber Technologies. This article breaks down strateg...